15 October 2015 Written by  Fierce Biotech

Semma Therapeutics named Fierce 15, Medical Devices 2015

Semma aims to create a beta cell device implant for Type 1 diabetes patients that could provide them with 5 to 7 years of insulin independence. The notion of beta cell replacement therapy is not a new one. The breakthrough that led to the creation of Semma was the ability to generate sufficient and well-functioning human pancreatic beta cells from undifferentiated pluripotent stem cells.

Read the full article from Fierce Biotech (HERE)